421 related articles for article (PubMed ID: 33616890)
1. Novel Therapy Approaches to Follicular Lymphoma.
Northend M; Townsend W
Drugs; 2021 Mar; 81(4):453-469. PubMed ID: 33616890
[TBL] [Abstract][Full Text] [Related]
2. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
[TBL] [Abstract][Full Text] [Related]
3. Follicular lymphoma: The long and winding road leading to your cure?
Gordon MJ; Smith MR; Nastoupil LJ
Blood Rev; 2023 Jan; 57():100992. PubMed ID: 35908982
[TBL] [Abstract][Full Text] [Related]
4. Advancements in the Management of Follicular Lymphoma: A Comprehensive Review.
Merryman R; Mehtap Ö; LaCasce A
Turk J Haematol; 2024 May; 41(2):69-82. PubMed ID: 38660754
[TBL] [Abstract][Full Text] [Related]
5. Follicular Lymphoma: a Focus on Current and Emerging Therapies.
Cahill KE; Smith SM
Oncology (Williston Park); 2022 Feb; 36(2):97-106. PubMed ID: 35180337
[TBL] [Abstract][Full Text] [Related]
6. Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies.
Hanel W; Epperla N
J Hematol Oncol; 2021 Jun; 14(1):104. PubMed ID: 34193230
[TBL] [Abstract][Full Text] [Related]
7. Thinking "outside the germinal center": Re-educating T cells to combat follicular lymphoma.
Kambhampati S; Shouse G; Danilov AV
Blood Rev; 2023 Sep; 61():101099. PubMed ID: 37173225
[TBL] [Abstract][Full Text] [Related]
8. Refining the management of relapsed or refractory follicular lymphoma.
Pagel JM; Burke JM; Leslie LA
Clin Adv Hematol Oncol; 2020 Dec; 18 Suppl 20(12):1-24. PubMed ID: 33843893
[TBL] [Abstract][Full Text] [Related]
9. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
Matarasso S; Assouline S
Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
[TBL] [Abstract][Full Text] [Related]
10. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.
Nastoupil LJ
Curr Hematol Malig Rep; 2021 Feb; 16(1):45-51. PubMed ID: 33797691
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapies for Follicular Lymphoma.
Girard J; Karimi Y; Carty S; Wilcox R; Kaminiski M; Malek S; Phillips T
Curr Hematol Malig Rep; 2021 Feb; 16(1):25-31. PubMed ID: 33754292
[TBL] [Abstract][Full Text] [Related]
12. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
Chiu H; Trisal P; Bjorklund C; Carrancio S; Toraño EG; Guarinos C; Papazoglou D; Hagner PR; Beldi-Ferchiou A; Tarte K; Delfau-Larue MH; Morschhauser F; Ramsay AG; Gandhi AK
Br J Haematol; 2019 Apr; 185(2):240-253. PubMed ID: 30767211
[TBL] [Abstract][Full Text] [Related]
13. Treating relapsed follicular lymphoma.
Erblich T; Montoto S
Expert Rev Hematol; 2018 May; 11(5):403-410. PubMed ID: 29542329
[TBL] [Abstract][Full Text] [Related]
14. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
16. Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.
Trotman J; Cheah CY; Marlton P; Opat S
Intern Med J; 2019 Apr; 49(4):422-433. PubMed ID: 30230156
[TBL] [Abstract][Full Text] [Related]
17. Recent landmark studies in follicular lymphoma.
Sorigue M; Sancho JM
Blood Rev; 2019 May; 35():68-80. PubMed ID: 30928169
[TBL] [Abstract][Full Text] [Related]
18. New developments in the treatment of follicular lymphoma.
Leonard JP
Rinsho Ketsueki; 2019; 60(9):1199-1204. PubMed ID: 31597844
[TBL] [Abstract][Full Text] [Related]
19. Translational insights into the genetics and immunobiology of relapsed/refractory follicular lymphoma.
Yaniv B; Tanenbaum B; Kazakova V; Patel SA
Leuk Res; 2024 Jul; 142():107519. PubMed ID: 38761562
[TBL] [Abstract][Full Text] [Related]
20. Divergent paths: management of early relapsed follicular lymphoma.
Takiar R; Karimi Y; Phillips TJ
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):666-675. PubMed ID: 36485106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]